Alembic Pharmaceuticals has secured final USFDA approval for its generic Olopatadine Hydrochloride Ophthalmic Solution (0.7%). Developed with Orbicular Pharmaceutical Technologies, the product targets a US market worth $20 million. This adds to Alembic's growing US portfolio, which now counts 248 total ANDA approvals.
Alembic Pharma Gets USFDA Nod for Allergy Eye Drops
Alembic Pharmaceuticals has received final USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, a generic version of Alcon’s Pataday Once Daily Relief.
The approval brings Alembic's cumulative ANDA count to 248, comprising 229 final and 19 tentative approvals.
Reader Takeaway: This expansion in the US generic market strengthens the ophthalmic portfolio, though the $20 million opportunity is niche.
What just happened
Alembic Pharmaceuticals secured regulatory clearance from the USFDA to manufacture and market Olopatadine Hydrochloride Ophthalmic Solution. This product is designed for the temporary relief of itchy eyes caused by common allergens like pollen, grass, and animal dander. The ANDA was developed in partnership with Orbicular Pharmaceutical Technologies Pvt Ltd, demonstrating the company's reliance on collaborative R&D to scale its US offerings.
Why this matters
For investors, this signifies steady execution in the company’s specialty generics business. While a $20 million market is relatively small compared to high-volume chronic therapies, it serves as a steady incremental revenue stream. The US remains a critical market for Alembic, and every approved ANDA enhances the company’s ability to compete in the highly regulated, high-margin generic eye-care space.
What to track next
Investors should monitor the commercial launch timeline and any potential competitive landscape shifts in the OTC ocular allergy segment. The effectiveness of the partnership with Orbicular will be a key metric to watch as the company continues to leverage external R&D capabilities for future filings.